The purpose of this study was to develop a tipranavir-weighted mutation score that provides guidance to treating physicians on the relative effect of specific protease mutations on tipranavir activity.
Methods
Weights were developed using data from RESIST tipranavir-treated patients based on regressions of virological response at weeks 8 and 24, accounting for baseline CD4+ T-cell count and background regimen activity. The resulting weighted score and cutoffs were validated using a set of cohort patients external to the tipranavir development programme. Response rates were tabulated for the new weighted score and compared with other tipranavir mutation scores used in clinical practice.
Results
The final weights were 74P, 82L/T, 83D and 47V (+4), 58E and 84V (+3), 36I, 43T and 54A/M/V (+2), 10V, 33F and 46L (+1), 24I and 76V (-2), 50L/V (-4), and 54L (-6). Tipranavir-weighted score susceptibility categories were susceptible ≤3, partially susceptible >3 but ≤10, and resistant ≥11. Week 48 response rates for RESIST patients were 34.6%, 15.9% and 5.9%, respectively. Using the external cohort data (n=150), the weighted score was highly associated with week 8 viral load reduction (P=0.0027). Only one other score achieved statistical significance.
Conclusions
The tipranavir-weighted score developed and externally validated here, in three datasets representing a broad population of treatment-experienced patients, can be used to make clinical decisions about whether to consider tipranavir in a treatment-experienced patient who has limited treatment options.
References
1.
HirschM.S., GunthardH.F., SchapiroJ.M.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society–USA panel.Clin Infect Dis2008; 47: 266–285.
2.
VandammeA.M., SönnerborgA., Ait-KhaledM.Updated European recommendations for the clinical use of HIV drug resistance testing.Antivir Ther2004; 9: 829–848.
3.
United States Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2008. (Updated 1 December 2009. Accessed 21 October 2009.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
4.
VermeirenH., Van CraenenbroeckE., AlenP.Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.J Virol Methods2007; 145: 47–55.
5.
ParkinN., ChappeyC.Protease mutations associated with higher or lower than expected tipranavir (TPV) susceptibility based on the TPV mutation score.13th Conference on Retroviruses and Opportunistic Infections. 5–8 February 2006, Denver, CO, USA. Poster 637.
6.
BaxterJ.D., SchapiroJ.M., BoucherC.A.Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.J Virol2006; 80: 10794–10801.
Van LaethemK., De LucaA., AntinoriA., CingolaniA., PernaC.F., VandammeA.M.A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.Antivir Ther2002; 7: 123–129.
WalmsleyS.L., KatlamaC., LazzarinA.Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone and in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).J Acquir Immune Defic Syndr2008; 47: 429–440.
HallD.B., SchapiroJ.M., BoucherC.A.B., BaxterJ.D., PilieroP., SchererJ.Development and performance of a trial-specific genotypic sensitivity score based on RESIST data that incorporates treatment history in addition to predicted susceptibility.Reviews in Antiviral Therapy2008; 2: 106.
14.
ParkinN.T., ChappeyC., PetropoulosC.J.Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.AIDS2003; 17: 955–961.
15.
PovedaE., de MendozaC., ParkinN.Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.AIDS2008; 22: 611–616.
